Sean Sheridan and Zlatina Dobreva discuss the importance of licensing intellectual property in the life sciences industry in the successful commercialization of early-stage therapeutics. Different licensing structures reflect the need for licensors and licensees to consider the range of paths for early-stage biotechnology development and then take all available and mutually agreeable steps to protect their interests. Read the full piece below.
Ken Beers joins CRA's Life Sciences Practice as Vice President
CRA is proud to welcome Kenneth J. Beers as a vice president in the Life Sciences Practice. Mr. Beers supports biopharmaceutical clients across a range of...